# reload+after+2024-01-21 10:32:41.358194
address1§3928 Point Eden Way
city§Hayward
state§CA
zip§94545
country§United States
phone§510 694 6200
website§https://www.arcusbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
fullTimeEmployees§500
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Terry J. Rosen Ph.D.', 'age': 63, 'title': 'Co-Founder, Chairman & CEO', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 756112, 'exercisedValue': 0, 'unexercisedValue': 4687920}, {'maxAge': 1, 'name': 'Dr. Juan Carlos Jaen Ph.D.', 'age': 65, 'title': 'Co-Founder, President & Director', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 931144, 'exercisedValue': 0, 'unexercisedValue': 3544951}, {'maxAge': 1, 'name': 'Mr. Robert C. Goeltz II', 'age': 50, 'title': 'Principal Financial Officer & CFO', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 745294, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jennifer A. Jarrett M.B.A.', 'age': 52, 'title': 'COO & Director', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 925294, 'exercisedValue': 0, 'unexercisedValue': 8332900}, {'maxAge': 1, 'name': 'Dr. Dimitry S.A. Nuyten M.D., Ph.D.', 'age': 47, 'title': 'Chief Medical Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 700337, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. K. Christopher  Garcia Ph.D.', 'title': 'Co-Founder & Member of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alexander  Azoy', 'age': 47, 'title': 'VP of Finance & Principal Accounting Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stephen  Young Ph.D.', 'age': 54, 'title': 'Senior Vice President of Technology & Quantitative Biology', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jonathan  Yingling Ph.D.', 'age': 54, 'title': 'Chief Scientific Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Katherine  Bock', 'title': 'Vice President of Investor Relations & Corporate Strategy', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§10
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.727
priceToSalesTrailing12Months§11.059915
currency§USD
dateShortInterest§1702598400
forwardEps§-4.08
exchange§NYQ
quoteType§EQUITY
shortName§Arcus Biosciences, Inc.
longName§Arcus Biosciences, Inc.
firstTradeDateEpochUtc§1521120600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§a42ee458-e105-39fd-912a-827d1ec1de8e
gmtOffSetMilliseconds§-18000000
targetHighPrice§70.0
targetLowPrice§23.0
targetMeanPrice§40.55
targetMedianPrice§36.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§11
quickRatio§4.275
grossMargins§-1.725
ebitdaMargins§-2.64167
trailingPegRatio§None
